Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis

Ren, Xing; Ai, Di; Li, Tong; Xia, Lei; Sun, Lingzhi

doi:10.3389/fneur.2020.603947

Cited by 14 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases with unmethylated MGMT, the addition of alternating electric fields therapy has shown promise in clinical trials and is included in front-line treatment in the National Comprehensive Cancer Network (NCCN) guidelines. Due to its tendency to be hypervascularized, the anti-angiogenic bevacizumab is commonly used as a second-line therapeutic in combination with agents like the alkylating mustard carmustine or lomustine [19][20][21]. Resistance to these therapies is based on two major factors: maintenance of stemness and overall dissemination.…”

Section: Figurementioning

confidence: 99%

Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma

Cornelison

Marrah

Horter

et al. 2021

IJMS

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope.

show abstract

Section: Figurementioning

confidence: 99%

Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma

Cornelison

Marrah

Horter

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Although the treatment of recurrent glioblastomas is not standardised, a follow up surgery (when feasible) and/or radiotherapy (rare) can be indicated in selected patients. The second line chemotherapy consists of either nitrosourea-based regimens, like lomustine (CCNU) alone, or the combination of lomustine plus alkylating agents (like TMZ) plus bevacizumab, or bevacizumab alone [69][70][71][72]. The use of lomustine in the treatment of recurrent glioblastoma provides a median overall survival of 8 to 9 months and a median progression-free survival of almost 3 months [72,73].…”

Section: Gbm Treatment Options and Novel Treatment Strategiesmentioning

confidence: 99%

Glioblastoma, from disease understanding towards optimal cell-based in vitro models

Boccellato

Rehm

2022

Cell Oncol.

View full text Add to dashboard Cite

Background Glioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into better characterizing and understanding this disease, and into developing novel research tools by which potential novel therapeutics and treatment options initially can be evaluated pre-clinically. Here, we provide a concise overview of glioblastoma epidemiology, disease classification, the challenges faced in the treatment of glioblastoma and current novel treatment strategies. From this, we lead into a description and assessment of advanced cell-based models that aim to narrow the gap between pre-clinical and clinical studies. Such invitro models are required to deliver reliable and meaningful data for the development and pre-validation of novel therapeutics and treatments. Conclusions The toolbox for GBM cell-based models has expanded substantially, with the possibility of 3D printing tumour tissues and thereby replicating invivo tissue architectures now looming on the horizon. A comparison of experimental cell-based model systems and techniques highlights advantages and drawbacks of the various tools available, based on which cell-based models and experimental approaches best suited to address a diversity of research questions in the glioblastoma research field can be selected.

show abstract

“…Bevacizumab (also known as Avastin) is the only effective therapeutic drug approved by the Food and Drug Administration (FDA) for the treatment of recurrent GBM (Wick et al, 2017). Recent studies have mainly focused on combined therapies with Avastin and radiation and/or chemical drugs; nevertheless, the results for the improvement of the survival rate of GBM patients are still not optimistic (Ren et al, 2021). Consequently, finding a promising therapeutic strategy and providing more efficient treatment options to patients with recurrent GBM have become the primary goals of oncologists.…”

Section: Introductionmentioning

confidence: 99%

Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways

et al. 2023

View full text Add to dashboard Cite

Background: Among central nervous system tumors, glioblastoma (GBM) is considered to be the most destructive malignancy. Recurrence is one of the most fatal aspects of GBM. However, the driver molecules that trigger GBM recurrence are currently unclear.Methods: The mRNA expression data and clinical information of GBM and normal tissues were collected from the Chinese Glioma Genome Atlas The Cancer Genome Atlas (TCGA), and REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) cohorts. The DESeq2 R package was used to identify the differentially expressed genes between primary and recurrent GBM. ClueGO, Kyoto Encyclopedia of Genes and Genomes (KEGG), Biological Process in Gene ontology (GO-BP), and the Protein ANalysis THrough Evolutionary Relationships (PANTHER) pathway analyses were performed to explore the enriched signaling pathways in upregulated DEGs in recurrent GBM. A gene list that contained potential oncogenes that showed a significant negative correlation with patient survival from The Cancer Genome Atlas was used to further screen driver candidates for recurrent GBM. Univariate Cox proportional hazards regression analyses were used to investigate the risk score for the mRNA expression of the candidates. Single-cell RNA sequencing (scRNA-Seq) analyses were used to determine the cell type-specific distribution of Fc gamma receptor II b (FcγRIIb) in GBM. Immunohistochemistry (IHC) was used to confirm the FcγRIIb-positive cell populations in primary and paired recurrent GBM.Results: Through DEG analysis and overlap analysis, a total of 10 genes that are upregulated in recurrent GBM were screened. Using validation databases, FcγRIIb was identified from the 10 candidates that may serve as a driver for recurrent GBM. FCGR2B expression, not mutation, further showed a highly negative correlation with the poor prognosis of patients with recurrent GBM. Furthermore, scRNA-Seq analyses revealed that tumor-associated macrophage- and dendritic cell-specific FCGR2B was expressed. Moreover, FcγRIIb also showed a strong positive correlation coefficient with major immune-associated signaling pathways. In clinical specimens, FcγRIIb-positive cell populations were higher in recurrent GBM than in primary GBM.Conclusion: This study provides novel insights into the role of FcγRIIb in recurrent GBM and a promising strategy for treatment as an immune therapeutic target.

show abstract

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis

Cited by 14 publications

References 31 publications

Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma

Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma

Glioblastoma, from disease understanding towards optimal cell-based in vitro models

Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways

Contact Info

Product

Resources

About